Advance Search
LIU Chunmei, LI Ming, ZHAO Gang. A systematic analysis in efficacy and safety of nimotuzumab combined with concurrent chemoradiotherapy in treatment of advanced esophageal cancer[J]. Journal of Clinical Medicine in Practice, 2021, 25(5): 10-15. DOI: 10.7619/jcmp.20201731
Citation: LIU Chunmei, LI Ming, ZHAO Gang. A systematic analysis in efficacy and safety of nimotuzumab combined with concurrent chemoradiotherapy in treatment of advanced esophageal cancer[J]. Journal of Clinical Medicine in Practice, 2021, 25(5): 10-15. DOI: 10.7619/jcmp.20201731
shu

A systematic analysis in efficacy and safety of nimotuzumab combined with concurrent chemoradiotherapy in treatment of advanced esophageal cancer

  • 1.

    Department of Oncology, Yongchuan Hospital Affiliated to Chongqing Medical University, Chongqing, 400000

  • 2.

    Department of Oncology, West China Hospital of Sichuan University, Chengdu, Sichuan, 610000

More Information
  • Received Date: December 19, 2020
  • Available Online: March 12, 2021
  • Published Date: March 14, 2021
    Graphical Abstract
    • Abstract
  •   Objective  To analyze the clinical effect of nitorzumab injection combined with concurrent chemoradiotherapy in the treatment of advanced esophageal cancer.
      Methods  The databases such as CNKI, Wanfang, VIP, China Biology Medicine (CBM), PubMed, Cochrane Library, Wiley Online Library and Google Academic were searched. The randomized controlled trials (RCT) of nituozumab combined with concurrent chemoradiotherapy (experimental group) and concurrent chemoradiotherapy (control group) were searched. The between-group differences of objective remission rate (ORR), disease control rate (DCR) and drug-related adverse reactions were analyzed by RevMan5.3 software.
      Results  Totally 9 studies were included, in which 8 studies were Chinese literatures and one study was foreign language literature. Meta-analysis showed that the ORR and DCR of the experimental group significantly improved and the incidence of adverse reactions was not increased.
      Conclusion  Efficacy and safety of nituozumab injection combined with concurrent chemoradiotherapy are reliable and definite. Rash and change of blood pressure may appear in the course of treatment, but the probability and the degree are relative low.
    • FullText(HTML)
    • References (21)
  • [1]
    HUANG F L, YU S J. Esophageal cancer: Risk factors, genetic association, and treatment[J]. Asian J Surg, 2018, 41(3): 210-215. doi: 10.1016/j.asjsur.2016.10.005
    [2]
    WATANABE M, OTAKE R, KOZUKI R, et al. Recent progress in multidisciplinary treatment for patients with esophageal cancer[J]. Surg Today, 2020, 50(1): 12-20. doi: 10.1007/s00595-019-01878-7
    [3]
    QIU M L, LIN J B, LI X, et al. Current state of esophageal cancer surgery in China: a national database analysis[J]. BMC Cancer, 2019, 19(1): 1064-1073. doi: 10.1186/s12885-019-6191-2
    [4]
    SINGH D, ATTRI B K, GILL R K, et al. Review on EGFR inhibitors: critical updates[J]. Mini Rev Med Chem, 2016, 16(14): 1134-1166. doi: 10.2174/1389557516666160321114917
    [5]
    VERA D R, EIGNER S, HENKE K E, et al. Preparation and preclinical evaluation of 177Lu-nimotuzumab targeting epidermal growth factor receptor overexpressing tumors[J]. Nucl Med Biol, 2012, 39(1): 3-13. doi: 10.1016/j.nucmedbio.2011.07.001
    [6]
    TSUCHIDA Y, THERASSE P. Response evaluation criteria in solid tumors (RECIST): new guidelines[J]. Med Pediatr Oncol, 2001, 37(1): 1-3. doi: 10.1002/mpo.1154
    [7]
    BATES D W, O'NEIL A C, PETERSEN L A, et al. Evaluation of screening criteria for adverse events in medical patients[J]. Med Care, 1995, 33(5): 452-462. doi: 10.1097/00005650-199505000-00002
    [8]
    CUMPSTON M, LI T, PAGE M J, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions[J]. Cochrane Database Syst Rev, 2019, 10: ED000142. http://www.researchgate.net/publication/336750574_Updated_guidance_for_trusted_systematic_reviews_a_new_edition_of_the_Cochrane_Handbook_for_Systematic_Reviews_of_Interventions
    [9]
    CLARK H D, WELLS G A, HUËT C, et al. Assessing the quality of randomized trials: reliability of the Jadad scale[J]. Control Clin Trials, 1999, 20(5): 448-452. doi: 10.1016/S0197-2456(99)00026-4
    [10]
    陈玉兰, 李曙平, 练英妮. 尼妥珠单抗联合奈达铂同步放化疗治疗局部晚期食管癌的临床研究[J]. 北方药学, 2016, 13(9): 140-141.
    [11]
    傅国林. 尼妥珠单抗在局部晚期食管癌同步放化疗中的疗效观察[J]. 中国基层医药, 2017, 24(22): 3457-3461. doi: 10.3760/cma.j.issn.1008-6706.2017.22.025
    [12]
    侯小霞, 常志伟, 秦艳茹. 尼妥珠单抗联合紫杉醇脂质体、顺铂同步放化疗治疗晚期食管癌的效果[J]. 河南医学研究, 2019, 28(12): 2144-2147. doi: 10.3969/j.issn.1004-437X.2019.12.010
    [13]
    黄丹丹, 李涛, 张军, 等. 尼妥珠单抗联合同步放化疗治疗局部晚期食管癌的近期疗效分析[J]. 中国肿瘤临床, 2012, 39(23): 1961-1963.
    [14]
    RAMOS-SUZARTE M, LORENZO-LUACES P, LAZO N G, et al. Treatment of malignant, non-resectable, epithelial origin esophageal tumours with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy[J]. Cancer Biol Ther, 2012, 13(8): 600-605. doi: 10.4161/cbt.19849
    [15]
    李明耀, 项振飞, 胡丹飞, 等. 尼妥珠单抗联合同步放化疗治疗局部晚期食管癌效果观察[J]. 中国乡村医药, 2018, 25(24): 15-16. doi: 10.3969/j.issn.1006-5180.2018.24.007
    [16]
    刘慧娟, 车宇, 刘佳. 尼妥珠单抗联合同步放、化疗治疗中晚期食管癌的近期疗效观察[J]. 现代肿瘤医学, 2015, 23(18): 2587-2590. doi: 10.3969/j.issn.1672-4992.2015.18.10
    [17]
    周云. 尼妥珠单抗联合洛铂同步放化疗治疗局部晚期食管癌的疗效分析[J]. 临床医药文献电子杂志, 2017, 4(84): 16603-16604. doi: 10.3877/j.issn.2095-8242.2017.84.094
    [18]
    张云霞, 张健. 尼妥珠单抗联合同步放化疗治疗局部晚期食管癌的短期疗效观察[J]. 心理医生, 2018, 24(25): 173-174.
    [19]
    FATEHI HASSANABAD A, CHEHADE R, BREADNER D, et al. Esophageal carcinoma: Towards targeted therapies[J]. Cell Oncol (Dordr), 2020, 43(2): 195-209.
    [20]
    郭晓彤, 赫捷. 食管癌治疗现状及精准医学时代展望[J]. 中华肿瘤杂志, 2016, 38(9): 641-645. doi: 10.3760/cma.j.issn.0253-3766.2016.09.001
    [21]
    TAYLOR RIPLEY R, SURMAN D R, DIGGS L P, et al. Metabolomic and BH3 profiling of esophageal cancers: novel assessment methods for precision therapy[J]. BMC Gastroenterol, 2018, 18(1): 94-99. doi: 10.1186/s12876-018-0823-x
    • Related Articles

  • Cited by

    Periodical cited type(17)

    1. 齐晏. 定向软通道治疗基底节区高血压脑出血的术后康复护理体会. 中国社区医师. 2021(33): 152-153 .
    2. 余娇，朱雪平. 脑电治疗仪联合康复护理在高血压性脑出血术后脑功能障碍患者中的应用. 医疗装备. 2020(03): 151-152 .
    3. 胡钜强，吴以艺，林球润. 基底节区脑出血软通道引流术的应用效果评价. 黑龙江医药. 2020(02): 385-387 .
    4. 陈旭文. 高血压脑出血术后瘫痪患者中运用早期康复护理的效果分析. 临床医药文献电子杂志. 2020(25): 62-63 .
    5. 陈小风. 早期康复护理对高血压脑出血颅内血肿清除术患者的并发症及生活能力的影响分析. 心血管病防治知识. 2020(25): 56-58 .
    6. 胡婷. 针对性护理干预在基底节区高血压脑出血患者围手术期中的应用. 黑龙江医药科学. 2019(02): 237-238 .
    7. 阮奶玲，游妹妹. 高血压护理教学实践中循证护理的运用效果观察. 心血管病防治知识(学术版). 2019(16): 68-69 .
    8. 段春芝，柯慧. 早期介入针刺结合现代康复护理用于脑出血术后临床疗效观察. 辽宁中医药大学学报. 2019(10): 204-207 .
    9. 顾华丽，赵艳君. 护患平行沟通法在基底节区高血压脑出血患者术后的应用价值. 河南医学研究. 2019(21): 3993-3995 .
    10. 赵月. 早期康复护理对高血压脑出血后遗症患者独立生活能力和负性情绪的作用分析. 世界最新医学信息文摘. 2019(85): 10-11 .
    11. 罗燕. 康复护理对高血压患者血压控制的影响. 现代诊断与治疗. 2019(19): 3475-3476 .
    12. 张珍珠，周巧玲. 小儿先天性心脏病实施以家庭为中心的术后康复护理效果观察. 心血管病防治知识(学术版). 2019(24): 74-76 .
    13. 吕雅飞，王燕锋，陈君霞，刘进. 早期康复护理对高血压脑出血后遗症患者独立生活能力和负性情绪的作用. 中国现代医生. 2019(35): 132-134+139 .
    14. 刘爱举. 不同康复介入时间对脑出血神经功能、日常生活能力的影响. 中国继续医学教育. 2018(17): 148-150 .
    15. 梁其志，伍益，昌大平. 定向软通道置软管血肿吸引术治疗高血压脑出血的疗效分析. 现代医院. 2018(01): 96-97+101 .
    16. 肖颖. 基底节区脑出血患者的围手术期护理. 中国现代药物应用. 2018(03): 137-138 .
    17. 霍峻峰，陈小兵. 软通道血肿抽吸术联合中药分期治疗高血压脑出血的效果. 深圳中西医结合杂志. 2018(19): 8-9 .

    Other cited types(1)

Catalog

    Get Citation
    PDF
    XML
    Article views PDF downloads Cited by(18)
    Turn off MathJax
    Article Contents
    Abstract
    References

    © 2020 《实用临床医药杂志》编辑部

    Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807

    苏公网安备 32100302010246号

    Supported by: Beijing Renhe Information Technology Co., Ltd.   Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return